Contact
Anaïs Van Meerbeck
Email
+32 (0)471 81 91 26
iTeos Therapeutics is a publicly held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Watertown, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011.
In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $230million of gross proceeds. In June 2021, iTeos entered into a transformative $2.145 billion co-development and co-commercialization agreement with GSK for EOS-448, iTeos’s anti-TIGITmonoclonal antibody. As a well-capitalized biotech company iTeos is positioned to continue to develop our clinical pipeline and maintain our investments in our discovery research team to leverage our fantastic science to improve the lives of cancer patients.
For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics is now a world-class actor in the sector. To carry on its growth and reinforce its team, iTeos Therapeutics is looking for a Research Assistant – Target Discovery & Validation.
We are looking for a highly motivated and skilled Research Assistant to join the Target Discovery and Validation group in the Research and Development Department. The successful candidate will perform laboratory work to support the selection and validation of innovative targets with the goal to develop breakthrough cancer immunotherapies.
More specifically, the successful candidate will be responsible for:
Your application and related information will remain strictly confidential.